Jörg Vervoorts

Jörg Vervoorts

Auto-generated profile, based on publicly available information

Jörg Vervoorts

Institute of Biochemistry and Molecular Biology, Medical School, RWTH Aachen University, Aachen, Germany

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
AMAntje Menssen
Antje Menssen
PHPer Hydbring
Per Hydbring
KKKarsten Kapelle
Karsten Kapelle
JVJörg Vervoorts
Jörg Vervoorts
JDJoachim Diebold
Joachim Diebold
Heiko HermekingHeiko Hermeking
Heiko Hermeking
Silent information regulator 1 (SIRT1) represents an NAD + -dependent deacetylase that inhibits proapoptotic factors including p53. Here we determined whether SIRT1 is downstream of the prototypic c- MYC oncogene, which is activated in the majority of tumors. Elevated expression of c-MYC in human colorectal cancer correlated with increased SIRT1 protein levels. Activation of a conditional c- MYC allele induced increased levels of SIRT1 protein, NAD + , and nicotinamide-phosphoribosyltransferase ( NAMPT ) mRNA in several cell types. This increase in SIRT1 required the induction of the NAMPT gene by c-MYC. NAMPT is the rate-limiting enzyme of the NAD + salvage pathway and enhances SIRT1 activity by increasing the amount of NAD + . c-MYC also contributed to SIRT1 activation by sequestering the SIRT1 inhibitor deleted in breast cancer 1 (DBC1) from the SIRT1 protein. In primary human fibroblasts previously immortalized by introduction of c-MYC, down-regulation of SIRT1 induced senescence and apoptosis. In various cell lines inactivation of SIRT1 by RNA interference, chemical inhibitors, or ectopic DBC1 enhanced c-MYC-induced apoptosis. Furthermore, SIRT1 directly bound to and deacetylated c-MYC. Enforced SIRT1 expression increased and depletion/inhibition of SIRT1 reduced c-MYC stability. Depletion/inhibition of SIRT1 correlated with reduced lysine 63-linked polyubiquitination of c-Myc, which presumably destabilizes c-MYC by supporting degradative lysine 48-linked polyubiquitination. Moreover, SIRT1 enhanced the transcriptional activity of c-MYC. Taken together, these results show that c-MYC activates SIRT1, which in turn promotes c-MYC function. Furthermore, SIRT1 suppressed cellular senescence in cells with deregulated c-MYC expression and also inhibited c-MYC–induced apoptosis. Constitutive activation of this positive feedback loop may contribute to the development and maintenance of tumors in the context of deregulated c-MYC.

4 April 2003 in EMBO Reports
Verified
Journal Article
Open access
PDF file
JVJörg Vervoorts
Jörg Vervoorts
JLJuliane M Lüscher‐Firzlaff
Juliane M Lüscher‐Firzlaff
SRSabine Rottmann
Sabine Rottmann
RLRichard Lilischkis
Richard Lilischkis
GWGesa Walsemann
Gesa Walsemann
BLBernhard Lüscher
Bernhard Lüscher
The c‐MYC oncoprotein regulates various aspects of cell behaviour by modulating gene expression. Here, we report the identification of the cAMP‐response‐element‐binding protein (CBP) as a novel c‐MYC binding partner. The two proteins interact both in vitro and in cells, and CBP binds to the carboxy‐terminal region of c‐MYC. Importantly, CBP, as well as p300, is associated with E‐box‐containing promoter regions of genes that are regulated by c‐MYC. Furthermore, c‐MYC and CBP/p300 function synergistically in the activation of reporter‐gene constructs. Thus, CBP and p300 function as positive cofactors for c‐MYC. In addition, c‐MYC is acetylated in cells. This modification does not require MYC box II, suggesting that it is independent of TRRAP complexes. Instead, CBP acetylates c‐MYC in vitro , and co‐expression of CBP with c‐MYC stimulates in vivo acetylation. Functionally, this results in a decrease in ubiquitination and stabilization of c‐MYC proteins. Thus, CBP and p300 are novel functional binding partners of c‐MYC.

1 November 2006 in Journal of Biological Chemistry
Verified
Journal Article
Open access
JVJörg Vervoorts
Jörg Vervoorts
JLJuliane Lüscher-Firzlaff
Juliane Lüscher-Firzlaff
BLBernhard Lüscher
Bernhard Lüscher
The proteins of the MYC family are key regulators of cell behavior. MYC, originally identified as an oncoprotein, affects growth, proliferation, differentiation, and apoptosis of cells through its ability to regulate a significant number of genes. In addition MYC governs events associated with tumor progression, including genetic stability, migration, and angiogenesis. The pleiotropic activities attributed to MYC and their balanced control requires that the expression and function of MYC is tightly controlled. Indeed many different pathways and factors have been identified that impinge on MYC gene expression and protein function. In particular the protein is subject to different posttranslational modifications, including phosphorylation, ubiquitinylation, and acetylation. Here we discuss the latest developments regarding these modifications that control various aspects of MYC function, including its stability, the interaction with partner proteins, and the transcriptional potential.

10 March 2008 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
RPRuwin Pandithage
Ruwin Pandithage
RLRichard Lilischkis
Richard Lilischkis
KHKai Harting
Kai Harting
AWAlexandra Wolf
Alexandra Wolf
BJBritta Jedamzik
Britta Jedamzik
BLBernhard Lüscher
Bernhard Lüscher
Cyclin-dependent kinases (Cdks) fulfill key functions in many cellular processes, including cell cycle progression and cytoskeletal dynamics. A limited number of Cdk substrates have been identified with few demonstrated to be regulated by Cdk-dependent phosphorylation. We identify on protein expression arrays novel cyclin E–Cdk2 substrates, including SIRT2, a member of the Sirtuin family of NAD+-dependent deacetylases that targets α-tubulin. We define Ser-331 as the site phosphorylated by cyclin E–Cdk2, cyclin A–Cdk2, and p35–Cdk5 both in vitro and in cells. Importantly, phosphorylation at Ser-331 inhibits the catalytic activity of SIRT2. Gain- and loss-of-function studies demonstrate that SIRT2 interfered with cell adhesion and cell migration. In postmitotic hippocampal neurons, neurite outgrowth and growth cone collapse are inhibited by SIRT2. The effects provoked by SIRT2, but not those of a nonphosphorylatable mutant, are antagonized by Cdk-dependent phosphorylation. Collectively, our findings identify a posttranslational mechanism that controls SIRT2 function, and they provide evidence for a novel regulatory circuitry involving Cdks, SIRT2, and microtubules.

29 December 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
PHPer Hydbring
Per Hydbring
FBFuad Bahram
Fuad Bahram
YSYingtao Su
Yingtao Su
STSusanna Tronnersjö
Susanna Tronnersjö
KHKari Högstrand
Kari Högstrand
LLLars-Gunnar Larsson
Lars-Gunnar Larsson
The MYC and RAS oncogenes are frequently activated in cancer and, together, are sufficient to transform rodent cells. The basis for this cooperativity remains unclear. We found that although Ras interfered with Myc-induced apoptosis, Myc repressed Ras-induced senescence, together abrogating two main barriers of tumorigenesis. Inhibition of cellular senescence required phosphorylation of Myc at Ser-62 by cyclin E/cyclin-dependent kinase (Cdk) 2. Cdk2 interacted with Myc at promoters, where it affected Myc-dependent regulation of genes, including Bmi-1 , p16 , p21 , and hTERT , which encode proteins known to control senescence. Repression of senescence by Myc was abrogated by the Cdk inhibitor p27Kip1, which is induced by antiproliferative signals like IFN-γ or by pharmacological inhibitors of Cdk2 but not by inhibitors of other Cdks. In contrast, a phospho-mimicking Myc-S62D mutant was resistant to these manipulations. Inhibition of cyclin E/Cdk2 reversed the senescence-associated gene expression pattern imposed by Myc/cyclin E/Cdk2. This indicates a role of Cdk2 as a transcriptional cofactor and activator of the antisenescence function of Myc and provides mechanistic insight into the Myc-p27Kip1 antagonism. Finally, our findings highlight that pharmacological inhibition of Cdk2 activity is a potential therapeutical principle for cancer therapy, in particular for tumors with activated Myc or Ras.

1 February 2012 in Gene
Verified
Journal Article
Closed access
BLBernhard Lüscher
Bernhard Lüscher
JVJörg Vervoorts
Jörg Vervoorts